Skip to main navigation Skip to main content

Page translation not available

This page is not available in the language that has been selected and will appear in English.

Search

Contact us

07 3737 4500

PO Box 3787

South Brisbane QLD 4101
Become a patient

Dr Paul De Ieso

MBBS, FRANZCR

  • Radiation Oncologist
Become a patient Refer a patient
Mulgrave
03 8726 1600 03 8726 1600
admin.mulgrave@icon.team

Biography

I provide a thoughtful, patient-centred radiation oncology service which focuses on using a strong evidence base to direct clinical decision-making. I pride myself on building strong and lasting relationships with my patients by listening to their concerns and keeping them well informed throughout their cancer journey.

Dr Paul De Ieso is an experienced radiation oncologist consulting at Icon Cancer Centre Mulgrave, Richmond, Freemasons and Moreland. In 2000, he completed his Bachelor of Medicine, Bachelor of Surgery (MBBS) degree at the University of Adelaide and became a fellow of the Royal Australian and New Zealand College of Radiologists (RANZCR) in 2009. Dr De Ieso completed specialist oncology training in London; he was awarded the RANZCR Windeyer Fellowship at Mount Vernon Cancer Centre and completed a three year Fellowship at the Royal Marsden Hospital. During his time in London, Dr De Ieso fostered strong professional relationships with medical and radiation oncologists that evolved into scientific publication and clinical collaborations.

In 2013, Dr De Ieso commenced his radiation oncology career in Darwin, providing much needed radiation oncology services to the people of the Top End of Australia. During his role, he provided satellite services to Alice Springs and was lead clinician for the introduction of the Northern Territory prospective prostate cancer clinical registry. He also was clinical lead for the introduction of Deep Inspiration Breath Hold (DIBH) techniques for breast cancer patients requiring radiation therapy.

With a number of first and co-authored cancer-related publications, involving various tumour sites, Dr De Ieso has a special interest in skin cancer, breast cancer, head and neck cancer, gastrointestinal cancer, urological cancers and soft tissue sarcomas. He is also passionate about the use of advanced radiation therapy technologies to reduce the side effects of therapy while optimising patient outcomes.

Publications

  • Immunohistochemical investigation of cytokine expression levels as biomarkers in transrectal ultrasound-guided needle biopsy specimens of prostate adenocarcinoma. Singh J, Thachil T, Eapen M. S., Lim A, Sufyan W, Rawson R, Duncan H, De Ieso P & Sohal S. S. Molecular and clinical oncology (2021), Volume 15, Issue 3, 191. 

  • Development of quality indicators to monitor radiotherapy care for men with prostate cancer: A modified Delphi method. Tsiamis E, Millar J, Baxi S, Borg M, De Ieso P, Elsaleh H, Foroudi F, Higgs B, Holt T, Martin J, Moretti K, Pryor D, Skala M, Evans S. Radiotherapy and Oncology (2018), Volume 128, Issue 2, 308 – 314. https://doi.org/10.1016/j.radonc.2018.04.017

  • Palliative chemoradiotherapy versus radiotherapy alone for dysphagia in advanced oesophageal cancer: a multicentre randomized controlled trial (TROG 03.01). Penniment M*, De Ieso P*, Harvey J, Stephens S, Au H, O’Callaghan C, Kneebone A, Ngan S, Ward I, Roy R, Smith J, Nijjar T, Biagi J, Mulroy L, Wong R. *Shared first authorship. The Lancet Gastroenterology and Hepatology (2018). https://doi.org/10.1016/S2468-1253(17)30363-1

  • Cytochrome P450 Allele CYP3A7*1C Associates with Adverse Outcomes in Chronic Lymphocytic Leukemia, Breast, and Lung Cancer. Johnson N, De Ieso P, Migliorini G, Orr N, Broderick P, Catovsky D, Matakidou A, Eisen T, Goldsmith C, Dudbridge F, Peto J, Dos-Santos-Silva I, Ashworth A, Ross G, Houlston RS, Fletcher O. Cancer Research (2016). http://cancerres.aacrjournals.org/content/76/6/1485

  • Development of Indicators to Assess Quality of Care for Prostate Cancer. Nag N, Millar J, Davis ID, Costello S, Duthie JB, Mark S, Delprado W, Smith D, Pryor D, Galvin D, Sullivan F, Murphy ÁC, Roder D, Elsaleh H, Currow D, White C, Skala M, Moretti KL, Walker T, De Ieso P, Brooks A, Heathcote P, Frydenberg M, Thavaseelan J, Evans SM. European Urology Focus (2016). https://doi.org/10.1016/j.euf.2016.01.016

  • Genetic predisposition to in situ and invasive lobular carcinoma of the breast. Sawyer E, Roylance R, Petridis C, Brook MN, Nowinski S, Papouli E, Fletcher O, Pinder S, Hanby A, Kohut K, Gorman P, Caneppele M, Peto J, dos Santos Silva I, Johnson N, Swann R, Dwek M, Perkins K, Gillett C, Houlston R, Ross G, De Ieso P, Southey MC et al. PLOS Genetics (2014);10(4):e1004285. https://doi.org/10.1371/journal.pgen.1004285

  • Long-term efficacy of fractionated radiotherapy for benign meningiomas. Francesca S, Wharram B, De Ieso P, Bonner J, Ashley S, Brada M. Radiotherapy and Oncology (2013), Volume 109, Issue 2, 330-334. https://doi.org/10.1016/j.radonc.2013.10.006

  • A study of the decision outcomes and financial costs of multidisciplinary team meetings (MDMs) in oncology. De Ieso PB, Coward JI, Letsa I, Schick U, Nandhabalan M, Frentzas S, Gore M. British Journal of Cancer (2013); 109, 2295-2300. https://www.nature.com/articles/bjc2013586#abstract

  • Image-guided vulvovaginal interstitial brachytherapy in the treatment of primary and recurrent vulvovaginal malignancies. De Ieso PB, Mullassery V, Shrimali R, Lowe G, Bryant L, Hoskin PJ. Brachytherapy (July – August 2012); 11(4):306-10. https://doi.org/10.1016/j.brachy.2011.08.002